S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.42 (-0.29%)
AAPL   139.07 (+1.61%)
MSFT   225.95 (+0.44%)
FB   274.50 (+0.60%)
GOOGL   1,892.56 (+0.45%)
AMZN   3,292.23 (-0.45%)
TSLA   846.64 (+0.20%)
NVDA   548.50 (-1.12%)
BABA   258.62 (-0.53%)
CGC   33.80 (+0.72%)
GE   11.11 (+0.36%)
MU   82.28 (-3.21%)
AMD   92.79 (+1.38%)
NIO   61.95 (+6.19%)
T   28.93 (+0.35%)
F   11.52 (-0.09%)
ACB   10.65 (-4.66%)
BA   205.84 (-0.76%)
DIS   172.78 (+0.88%)
NFLX   565.17 (-2.53%)
GILD   66.94 (-0.06%)
S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.42 (-0.29%)
AAPL   139.07 (+1.61%)
MSFT   225.95 (+0.44%)
FB   274.50 (+0.60%)
GOOGL   1,892.56 (+0.45%)
AMZN   3,292.23 (-0.45%)
TSLA   846.64 (+0.20%)
NVDA   548.50 (-1.12%)
BABA   258.62 (-0.53%)
CGC   33.80 (+0.72%)
GE   11.11 (+0.36%)
MU   82.28 (-3.21%)
AMD   92.79 (+1.38%)
NIO   61.95 (+6.19%)
T   28.93 (+0.35%)
F   11.52 (-0.09%)
ACB   10.65 (-4.66%)
BA   205.84 (-0.76%)
DIS   172.78 (+0.88%)
NFLX   565.17 (-2.53%)
GILD   66.94 (-0.06%)
S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.42 (-0.29%)
AAPL   139.07 (+1.61%)
MSFT   225.95 (+0.44%)
FB   274.50 (+0.60%)
GOOGL   1,892.56 (+0.45%)
AMZN   3,292.23 (-0.45%)
TSLA   846.64 (+0.20%)
NVDA   548.50 (-1.12%)
BABA   258.62 (-0.53%)
CGC   33.80 (+0.72%)
GE   11.11 (+0.36%)
MU   82.28 (-3.21%)
AMD   92.79 (+1.38%)
NIO   61.95 (+6.19%)
T   28.93 (+0.35%)
F   11.52 (-0.09%)
ACB   10.65 (-4.66%)
BA   205.84 (-0.76%)
DIS   172.78 (+0.88%)
NFLX   565.17 (-2.53%)
GILD   66.94 (-0.06%)
S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.42 (-0.29%)
AAPL   139.07 (+1.61%)
MSFT   225.95 (+0.44%)
FB   274.50 (+0.60%)
GOOGL   1,892.56 (+0.45%)
AMZN   3,292.23 (-0.45%)
TSLA   846.64 (+0.20%)
NVDA   548.50 (-1.12%)
BABA   258.62 (-0.53%)
CGC   33.80 (+0.72%)
GE   11.11 (+0.36%)
MU   82.28 (-3.21%)
AMD   92.79 (+1.38%)
NIO   61.95 (+6.19%)
T   28.93 (+0.35%)
F   11.52 (-0.09%)
ACB   10.65 (-4.66%)
BA   205.84 (-0.76%)
DIS   172.78 (+0.88%)
NFLX   565.17 (-2.53%)
GILD   66.94 (-0.06%)
Log in
ASX:IMM

Immutep Limited (IMM.AX) Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
A$0.15
MA: A$0.15
A$0.15
52-Week Range N/A
Volume2.15 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as Â'eftilagimod alpha' or Â'efti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.

MarketRank

Overall MarketRank

0.50 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 2 8315 7003
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$13.74 million
Book ValueA$0.07 per share

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

Receive IMM News and Ratings via Email

Sign-up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Immutep Limited (IMM.AX) (ASX:IMM) Frequently Asked Questions

What stocks does MarketBeat like better than Immutep Limited (IMM.AX)?

Wall Street analysts have given Immutep Limited (IMM.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Immutep Limited (IMM.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Immutep Limited (IMM.AX)'s earnings last quarter?

Immutep Limited (IMM.AX) (ASX:IMM) announced its quarterly earnings results on Wednesday, February, 27th. The company reported $0.00 earnings per share for the quarter.
View Immutep Limited (IMM.AX)'s earnings history
.

Who are some of Immutep Limited (IMM.AX)'s key competitors?

What other stocks do shareholders of Immutep Limited (IMM.AX) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immutep Limited (IMM.AX) investors own include ICL Group (ICL), Geron (GERN), Immersion (IMMR), Innovative Industrial Properties (IIPR), Evoke Pharma (EVOK), Enphase Energy (ENPH), DURECT (DRRX), Denali Therapeutics (DNLI), Cynata Therapeutics Limited (CYP.AX) (CYP) and Yamana Gold (AUY).

Who are Immutep Limited (IMM.AX)'s key executives?

Immutep Limited (IMM.AX)'s management team includes the following people:
  • Mr. Marc Voigt, CEO, CFO, Chief Bus. Officer & Exec. Director (Age 48, Pay $456.42k)
  • Ms. Deanne Miller, COO, Gen. Counsel & Joint Company Sec. (Age 44, Pay $280.12k)
  • Dr. Frederic Triebel, Chief Scientific Officer & Chief Medical Officer (Age 66, Pay $279.12k)
  • Ms. Indira Naidu, Joint Company Sec.
  • Mr. Christian Mueller, Director of Clinical Devel. & Regulatory Affairs
  • Mr. Shengfei Fang, Fin. Director & Assistant Company Sec.

What is Immutep Limited (IMM.AX)'s stock symbol?

Immutep Limited (IMM.AX) trades on the ASX under the ticker symbol "IMM."

How big of a company is Immutep Limited (IMM.AX)?

Immutep Limited (IMM.AX) has a market capitalization of $0.00 and generates $13.74 million in revenue each year.

What is Immutep Limited (IMM.AX)'s official website?

The official website for Immutep Limited (IMM.AX) is www.primabiomed.com.au.

How can I contact Immutep Limited (IMM.AX)?

The company can be reached via phone at 61 2 8315 7003.

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.